This is illustrated by the report of three patients with metastatic melanoma and strong immunohistochemical c-KIT expression who did not respond to a therapy with the c-KIT blocker imatinib (Alexis et al, 2005). The gene discussed is KIT; the disease is metastatic melanoma.